SK Bioscience, Q1 Operating Profit 53.7 Billion KRW... 'Return to Profitability'
[Asia Economy Reporter Kim Ji-hee] SK Bioscience announced on the 3rd that its operating profit for the first quarter of this year reached 53.7 billion KRW, achieving a turnaround to profitability. During the same period, sales increased by 422.4% to 112.7 billion KRW, marking the highest quarterly performance.
Net profit also turned positive. While recording a loss of 5.8 billion KRW in the first quarter of last year, it posted a profit of 41.9 billion KRW in the most recent first quarter.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 40s Who Kept Girlfriend's Body for a Year After Murder Sentenced to 30 Years in Prison Again on Appeal
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
An SK Bioscience official stated, "In the first quarter, production and shipment of commercial volumes of the AstraZeneca vaccine were carried out," adding, "From the second quarter onward, the effects of contract manufacturing of the Novavax COVID-19 vaccine will be reflected, and the performance growth trend is expected to continue."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
